Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ...

One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...